JP Morgan Chase
VRTX icon

JP Morgan Chase’s Vertex Pharmaceuticals VRTX Stock Holding History

JP Morgan Chase’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.4M Buy
111,500
+22,200
+25% +$10.4M ﹤0.01% 1407
2025
Q4 		$40.5M Sell
89,300
-42,500
-32% -$18.3M ﹤0.01% 1503
2025
Q3 		$51.6M Buy
131,800
+124,300
+1,657% +$51.9M ﹤0.01% 1394
2025
Q2 		$3.34M Sell
7,500
-24,000
-76% -$11.1M ﹤0.01% 3510
2025
Q1 		$15.3M Sell
31,500
-14,800
-32% -$6.9M ﹤0.01% 2152
2024
Q4 		$18.6M Sell
46,300
-75,000
-62% -$34.8M ﹤0.01% 2109
2024
Q3 		$56.4M Buy
121,300
+89,600
+283% +$43M ﹤0.01% 1255
2024
Q2 		$14.9M Sell
31,700
-10,300
-25% -$4.47M ﹤0.01% 2114
2024
Q1 		$17.6M Sell
42,000
-4,000
-9% -$1.69M ﹤0.01% 1995
2023
Q4 		$18.7M Buy
46,000
+5,500
+14% +$2.03M ﹤0.01% 1916
2023
Q3 		$14.1M Buy
40,500
+22,400
+124% +$7.83M ﹤0.01% 1965
2023
Q2 		$6.37M Buy
18,100
+11,200
+162% +$3.77M ﹤0.01% 2675
2023
Q1 		$2.17M Sell
6,900
-48,200
-87% -$14.5M ﹤0.01% 3484
2022
Q4 		$15.9M Buy
55,100
+3,700
+7% +$1.13M ﹤0.01% 1848
2022
Q3 		$14.9M Hold
51,400
– – ﹤0.01% 1816
2022
Q2 		$14.5M Buy
51,400
+36,400
+243% +$9.74M ﹤0.01% 1881
2022
Q1 		$3.92M Buy
15,000
+14,500
+2,900% +$3.44M ﹤0.01% 3211
2021
Q4 		$110K Hold
500
– – ﹤0.01% 5633
2021
Q3 		$91K Hold
500
– – ﹤0.01% 5619
2021
Q2 		$101K Sell
500
-324,600
-100% -$67.9M ﹤0.01% 5541
2021
Q1 		$69.9M Buy
+325,100
New +$71.4M 0.01% 1024
2020
Q3 		– Sell
-40,000
Closed -$11.6M – 5813
2020
Q2 		$11.6M Sell
40,000
-44,800
-53% -$12.1M ﹤0.01% 1779
2020
Q1 		$20.2M Buy
84,800
+52,000
+159% +$11.9M ﹤0.01% 1256
2019
Q4 		$7.18M Buy
32,800
+11,200
+52% +$2.27M ﹤0.01% 2399
2019
Q3 		$3.66M Buy
21,600
+8,800
+69% +$1.56M ﹤0.01% 2956
2019
Q2 		$2.29M Sell
12,800
-126,800
-91% -$22.2M ﹤0.01% 3291
2019
Q1 		$25.7M Buy
139,600
+118,700
+568% +$21.9M 0.01% 1373
2018
Q4 		$3.46M Sell
20,900
-4,600
-18% -$797K ﹤0.01% 2860
2018
Q3 		$4.92M Sell
25,500
-41,100
-62% -$7.32M ﹤0.01% 2760
2018
Q2 		$11.3M Buy
66,600
+13,200
+25% +$2.05M ﹤0.01% 2042
2018
Q1 		$8.7M Buy
53,400
+46,500
+674% +$7.6M ﹤0.01% 2124
2017
Q4 		$1.03M Buy
6,900
+400
+6% +$59.2K ﹤0.01% 3709
2017
Q3 		$973K Buy
+6,500
New +$978K ﹤0.01% 3532
2017
Q2 		– Sell
-67,500
Closed -$7.38M – 5245
2017
Q1 		$7.38M Buy
+67,500
New +$5.94M ﹤0.01% 2146
2016
Q4 		– Sell
-25,000
Closed -$2.18M – 5151
2016
Q3 		$2.18M Buy
+25,000
New +$2.36M ﹤0.01% 2746
2015
Q2 		– Sell
-4,000
Closed -$472K – 4197
2015
Q1 		$472K Buy
+4,000
New +$479K ﹤0.01% 3556

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

JP Morgan Chase's VRTX Position: Q1 2026 in Review

JP Morgan Chase increased its Vertex Pharmaceuticals (VRTX) stake by 16% in Q1 2026, buying an estimated $463M and bringing the position to 7,033,156 shares worth $3.12B. The position accounts for 0.2% of the portfolio, ranked #109.

JP Morgan Chase first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.76B in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • JP Morgan Chase held 7,033,156 shares of Vertex Pharmaceuticals worth $3.12B as of Q1 2026.
  • JP Morgan Chase bought 993,675 Vertex Pharmaceuticals shares in Q1 2026, an estimated $463M.
  • Vertex Pharmaceuticals made up 0.2% of JP Morgan Chase's portfolio in Q1 2026, its #109 holding.
  • JP Morgan Chase first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • JP Morgan Chase's Vertex Pharmaceuticals position peaked at $3.76B in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.